Creation of a commercial pilot line at RiTdisplay is a significant step towards commercialization of Smartkem's OTFT technology MANCHESTER, England, March 24, 2025 /PRNewswire/ -- Smartkem ...

Muzastotug Phase 2 dose expansion in MSS CRC with a 20 mg/kg loading dose regimen shows 33% overall response rate with four confirmed partial responses SAFEbody technology utilized to create masked ...